Market Overview

Why Beam Therapeutics Is Trading Higher Today

Why Beam Therapeutics Is Trading Higher Today

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher on Wednesday after William Blair initiated coverage on the company's stock with an Outperform rating and announced a $33 price target.

Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises of Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.

Beam Therapeutics shares were trading up 8.55% to $21.07 at time of publication on Wednesday. The stock has a 52-week high of $31.80 and a 52-week low of $13.

Latest Ratings for BEAM

Aug 2020William BlairInitiates Coverage OnOutperform
Mar 2020WedbushInitiates Coverage OnOutperform
Mar 2020BarclaysInitiates Coverage OnOverweight

View More Analyst Ratings for BEAM
View the Latest Analyst Ratings


Related Articles (BEAM)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Initiation Analyst Ratings

Latest Ratings

JBLRBC CapitalMaintains38.0
COSTRBC CapitalMaintains412.0
COSTMKM PartnersMaintains325.0
MTNTruist SecuritiesMaintains243.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at